Literature DB >> 23337599

N-1, C-3 substituted indoles as 5-LOX inhibitors--in vitro enzyme immunoaasay, mass spectral and molecular docking investigations.

Palwinder Singh1.   

Abstract

Based upon the structures of some known 5-LOX inhibitors, a set of five compounds carrying appropriate substituents at N-1 and C-3 of indole were synthesized and investigated for 5-LOX inhibitory activities. Fifty percent inhibitory concn (IC(50)) of these compounds ranges from 0.6 to 5 μM and found to be comparable to that of clinically used 5-LOX inhibitor, zileuton. The compounds under present investigations exhibited appreciable interactions with 5-LOX as apparent from their association constants calculated from the mass spectral data. Compound 5a with a tosyl group at N-1 and pyrolidinyl-1,2-dione substituent at C-3 of indole, exhibiting IC(50) 0.6 μM and stoichiometry of 1:7 in the enzyme-compound complex was identified as highly potent 5-LOX inhibitor and seems to be suitable for further investigations.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23337599     DOI: 10.1016/j.bmcl.2012.12.068

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

1.  Computer modeling in predicting the bioactivity of human 5-lipoxygenase inhibitors.

Authors:  Mengdi Zhang; Zhonghua Xia; Aixia Yan
Journal:  Mol Divers       Date:  2016-11-30       Impact factor: 2.943

Review 2.  Recent development of lipoxygenase inhibitors as anti-inflammatory agents.

Authors:  Chaoyu Hu; Shutao Ma
Journal:  Medchemcomm       Date:  2017-11-29       Impact factor: 3.597

Review 3.  Looking at NSAIDs from a historical perspective and their current status in drug repurposing for cancer treatment and prevention.

Authors:  Adem Ozleyen; Yakup Berkay Yilmaz; Serhat Donmez; Hazal Nazlıcan Atalay; Gizem Antika; Tugba Boyunegmez Tumer
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-25       Impact factor: 4.322

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.